Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Inhibikase Therapeutics (IKT) Ownership Overview
9.83% Insiders
3.95% Mutual Funds
61.65% Other Institutional Investors
3.71% ETFs
20.86% Public Companies and
Individual Investors
The ownership structure of Inhibikase Therapeutics (IKT) stock is a mix of institutional, retail, and individual investors. Approximately 69.32% of the company’s stock is owned by Institutional Investors, 9.83% is owned by Insiders, and 20.86% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Oct 23, 2024 | xxxxxxxxxxxxx | $500050 | |
| Oct 23, 2024 | xxxxxxxxxxxxx | $2000200 | |
| Oct 23, 2024 | xxxxxxxxxxxxx | $198650 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $6729723 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $19256250 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $19906250 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,125,000 | Institution | 8.24% | 12,127,500 | |
| 5,925,000 | Institution | 7.97% | 11,731,500 | |
| 5,335,433 | Insider | 7.18% | 10,564,157 | |
| 2,760,750 | Institution | 3.71% | 5,466,285 | |
| 2,760,750 | Institution | 3.71% | 5,466,285 | |
| 2,070,684 | Institution | 2.79% | 4,099,954 | |
| 1,460,000 | Insider | 1.96% | 2,890,800 | |
| 365,000 | Insider | 0.49% | 722,700 | |
| 145,000 | Insider | 0.20% | 287,100 | |
| 59,477 | Institution | 0.08% | 117,764 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,760,750 | Institution | 3.71% | 5,466,285 | |
| 59,477 | Institution | 0.08% | 117,764 | |
| 44,358 | Institution | 0.06% | 87,829 | |
| 35,000 | Institution | 0.05% | 69,300 | |
| 33,537 | Institution | 0.05% | 66,403 | |
| 6,316 | Institution | <0.01% | 12,506 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,277,400 | Institution | 3.06% | 5,238,020 | |
| 483,350 | Institution | 0.65% | 1,111,705 |
FAQ
Who Owns Inhibikase Therapeutics (IKT)?
According to the latest TipRanks data, approximately 61.65% of the company's stock is held by institutional investors, 9.83% is held by insiders, and 20.86% is held by retail investors.
What percentage of Inhibikase Therapeutics (IKT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 61.65% of Inhibikase Therapeutics (IKT) stock is held by institutional investors.
What percentage of Inhibikase Therapeutics (IKT) stock is held by retail investors?
According to the latest TipRanks data, approximately 20.86% of Inhibikase Therapeutics (IKT) stock is held by retail investors.
Who owns the most shares of Inhibikase Therapeutics (IKT)?
Peter Harwin owns the most shares of Inhibikase Therapeutics (IKT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.